# Study of ZG005 in Patients With Advanced Solid Tumors

> **NCT06927687** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd** · enrollment: 50 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **BIOLOGICAL:** ZG005 for Injection

## Key facts

- **NCT ID:** NCT06927687
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-06-13
- **Primary completion:** 2027-05
- **Final completion:** 2027-06
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06927687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06927687, "Study of ZG005 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT06927687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*